biotech investing Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
biotech investing Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
biotech investing Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab in Osteogenesis Imperfecta
biotech investing Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
NevGold Announces Up To 53.7% Antimony, And Fourteen Samples Over 2% Antimony, From Surface Sampling On Pre-Strip Dump